Result:Poor· Market: Crashed#Margin squeeze
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 9.10 | 43.8% | 28.4% |
| Total Income | 11.36 | 40.7% | 21.5% |
| Expenditure | 11.41 | 34.6% | 1.9% |
| PBT | -0.05 | 103.2% | 101.7% |
| Net Profit | -0.04 | 103.6% | 101.7% |
| OPM | -18.64% | 14.53pp | 33.99pp |
| NPM | -0.37% | 6.39pp | 17.18pp |
| EPS | 0.04 | 96.2% | 98.3% |
Pharma/manufacturing core metrics deteriorated sharply — revenue down 28.4% YoY and OPM collapsed from 15.35% to -18.64%, driving a swing from ₹2.43cr profit to a net loss (not a turnaround).
Informational and educational content only. Not investment advice.